Nektar Therapeutics (NKTR) revealed Loss for first quarter that decreased from last year in line with the Street estimates.
The company's bottom line totaled -$36.80 million, or -$0.19 per share. This compares with -$137.02 million, or -$0.73 per share, in last year's first quarter.
Analysts on average had expected the company to earn -$0.19 per share, according to figures compiled by Thomson Reuters. Analysts' estimates typically exclude special items.
The company's revenue for the quarter rose 0.2% to $21.64 million from $21.59 million last year.
Nektar Therapeutics earnings at a glance (GAAP) :
-Earnings (Q1): -$36.80 Mln. vs. -$137.02 Mln. last year.-EPS (Q1): -$0.19 vs. -$0.73 last year.-Revenue (Q1): $21.64 Mln vs. $21.59 Mln last year.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.